29 results on '"Proniuk, Stefan"'
Search Results
2. 645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors
3. Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes
4. A single-dose PK study of onapristone including the effect of food on absorption
5. ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA
6. Some Important Considerations in the Use of Cyclodextrins
7. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
8. AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication
9. The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions
10. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
11. AR-12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication
12. Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.
13. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
14. AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins
15. Abstract 4512: Onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers: PK results from part 1 of a randomized, parallel-dose phase 1 study
16. Abstract 4523: Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers
17. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.
18. Abstract 1646: Synthesis of [11C]onapristone for clinical investigation
19. Abstract 4636: Pharmacokinetic (PK) food effect study of immediate-release onapristone and its primary metabolite (M1) in healthy female subjects: implications for design of a new formulation
20. A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).
21. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
22. Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention
23. Anhydrous Carbopol® Polymer Gels for the Topical Delivery of Oxygen/Water Sensitive Compounds
24. Topical Formulation Studies with DEET (N,N‐Diethyl‐3‐methylbenzamide) and Cyclodextrins
25. Effect of Temperature and Light on the Stability of Latanoprost and its Clinical Relevance
26. Influence of degree of substitution of cyclodextrins on their colligative properties in solution
27. Investigation of the Utility of an In Vitro Release Test for Optimizing Semisolid Dosage Forms
28. Topical formulation studies with DEET (<TOGGLE>N,N</TOGGLE>-diethyl-3-methylbenzamide) and cyclodextrins
29. A Simplified and Rapid High-Performance Liquid Chromatographic Assay for Ketoprofen in Isopropyl Myristate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.